JEAN-FRANCOIS LEPRINCE

Managing Partner Funds I & II

Mr Leprince comes to CTI LSF from his position as President and CEO of Aventis Pharma Canada. Mr. Leprince brings over 30 years of experience with large pharmaceutical companies to the table along with firsthand knowledge of overseeing the largest R&D spend of any of the multinational pharmaceutical companies operating in Canada. Mr. Leprince also brings valuable experience on the operational perspectives of overseeing new products through development to market; and the financial wherewithal to accomplish this. He is a retired board member of AllerGen and serves as the Chairman of the Board of IRICoR, two organizations which are part of the Networks of Centres of Excellence of Canada. He serves also as a board member of the Institut en Recherche en Immunologie et Cancérologie (IRIC) de l'Université de Montréal. Mr. Leprince holds a bachelor degree in chemical engineering from Institut National Supérieur de Chimie Industrielle de Rouen, France.